PMID: 11328303May 1, 2001Paper

Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma

British Journal of Haematology
C I ChenA Keating

Abstract

Histological transformation from a follicular non-Hodgkin's lymphoma (NHL) to a higher grade lymphoma carries a poor prognosis despite treatment with aggressive anthracycline-based chemotherapy. We retrospectively analysed 35 patients with histologically transformed NHL who underwent high-dose therapy and autotransplantation at our centre. Patients up to 65 years old were eligible for autotransplant at the time of transformation or with subsequent relapses, provided that chemosensitivity to a salvage regimen could be demonstrated. All patients received high-dose therapy [etoposide 60 mg/kg, melphalan 160 mg/m2 and fractionated total body irradiation (TBI) 12 Gy] followed by unpurged autologous bone marrow or blood stem cell rescue. Most patients (69%) had advanced stage disease (stages 3--4) at transformation and bone marrow involvement was common (49%). Twenty-six (74%) patients were in partial remission (PR) and nine (26%) in complete remission (CR) at the time of transplant. Median duration from transformation to transplant was 10.9 months (range, 5.2 months--4.6 years). At a median follow up of 52 months after autotransplant, 19 (54%) patients had died. Causes of death were progressive lymphoma in nine patients (26%), treat...Continue Reading

References

May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A S FreedmanL Heflin
Feb 1, 1989·European Journal of Haematology·J ErsbøllN I Nissen
Oct 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C J GallagherT A Lister
Jan 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B AckerS A Rosenberg
Dec 6, 1984·The New England Journal of Medicine·S J Horning, S A Rosenberg
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A R YuenS J Horning
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W MillsA H Goldstone
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M VoseJ O Armitage
Mar 1, 1994·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·R C VannucciS J Vannucci
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Jul 1, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C GirouardM Crump
Oct 28, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J M ForanA Z Rohatiner
Aug 28, 1999·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·J W FriedbergA S Freedman

❮ Previous
Next ❯

Citations

Aug 12, 2006·Current Oncology Reports·Andrew J Davies
Aug 7, 2012·Current Oncology Reports·Eric Wong, Michael Dickinson
Sep 10, 2003·Seminars in Cancer Biology·Jürgen Finke
Jul 9, 2008·Nature Clinical Practice. Oncology·Luciano Wannesson, Emanuele Zucca
Feb 22, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D VillaJ Kuruvilla
Sep 21, 2006·Clinical Nuclear Medicine·Andrew F RobertsonPaul J Roach
Dec 17, 2009·Hematology·Steven H Bernstein, W Richard Burack
Aug 29, 2009·PharmacoEconomics·Talia FosterMason W Russell
Feb 6, 2007·British Journal of Haematology·Andrew J DaviesT Andrew Lister
Oct 12, 2013·British Journal of Haematology·Makiko Ban-HoefenJonathan W Friedberg
Dec 17, 2014·Blood·Carla CasuloJonathan W Friedberg
Jan 10, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ginna G Laport
Mar 20, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Baldeep WirkWael Saber
Dec 8, 2015·Hematology·Silvia Montoto
Feb 2, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Denise M OlianskyTheresa Hahn
Apr 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Issa F KhouriRichard E Champlin
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Diego VillaJohn Kuruvilla
Aug 7, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Constantine S TamJohn F Seymour
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirsty J ThomsonStephen Mackinnon
Jun 15, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Clémentine SarkozyHervé Tilly
Jul 22, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Diego VillaJohn Kuruvilla
Nov 28, 2016·Hematology/oncology Clinics of North America·Mary Ann AndersonJohn F Seymour
Oct 19, 2004·Bone Marrow Transplantation·W W TseK Van Besien
Apr 15, 2003·Bone Marrow Transplantation·R E Lerner, L J Burns
Apr 7, 2018·Journal of Cancer Research and Clinical Oncology·Frank HeinzelmannHellmut Ottinger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.